DICER1 syndrome is a rare genetic condition predisposing to hereditary cancer and caused by variants in the DICER1 gene. The risk to present a neoplasm before the age of 10 years is 5.3 and 31.5% before the age of 60. DICER1 variants have been associated with a syndrome involving familial pleuropulmonary blastoma (PPB), a rare malignant tumor of the lung, which occurs primarily in children under the age of 6 years and represents the most common life-threatening manifestation of DICER1 syndrome. Type I, II, III, and Ir (type I regressed) PPB are reported with a 5-year overall survival ranging from 53 to 100% (for type Ir). DICER1 gene should be screened in all patients with PPB and considered in other tumors mainly in thyroid neoplasms (multinodular goiter, thyroid cancer, adenomas), ovarian tumors (Sertoli-Leydig cell tumor, sarcoma, and gynandroblastoma), and cystic nephroma. A prompt identification of this syndrome is necessary to plan a correct follow-up and screening during lifetime.

Caroleo, A. M., De Ioris, M. A., Boccuto, L., Alessi, I., Del Baldo, G., Cacchione, A., Agolini, E., Rinelli, M., Serra, A., Carai, A., Mastronuzzi, A., DICER1 Syndrome and Cancer Predisposition: From a Rare Pediatric Tumor to Lifetime Risk, <<FRONTIERS IN ONCOLOGY>>, 2021; 10 (10): 1-7. [doi:10.3389/fonc.2020.614541] [https://hdl.handle.net/10807/330022]

DICER1 Syndrome and Cancer Predisposition: From a Rare Pediatric Tumor to Lifetime Risk

Carai, Andrea
Penultimo
Writing – Review & Editing
;
Mastronuzzi, Angela
Ultimo
Writing – Review & Editing
2021

Abstract

DICER1 syndrome is a rare genetic condition predisposing to hereditary cancer and caused by variants in the DICER1 gene. The risk to present a neoplasm before the age of 10 years is 5.3 and 31.5% before the age of 60. DICER1 variants have been associated with a syndrome involving familial pleuropulmonary blastoma (PPB), a rare malignant tumor of the lung, which occurs primarily in children under the age of 6 years and represents the most common life-threatening manifestation of DICER1 syndrome. Type I, II, III, and Ir (type I regressed) PPB are reported with a 5-year overall survival ranging from 53 to 100% (for type Ir). DICER1 gene should be screened in all patients with PPB and considered in other tumors mainly in thyroid neoplasms (multinodular goiter, thyroid cancer, adenomas), ovarian tumors (Sertoli-Leydig cell tumor, sarcoma, and gynandroblastoma), and cystic nephroma. A prompt identification of this syndrome is necessary to plan a correct follow-up and screening during lifetime.
2021
Inglese
Caroleo, A. M., De Ioris, M. A., Boccuto, L., Alessi, I., Del Baldo, G., Cacchione, A., Agolini, E., Rinelli, M., Serra, A., Carai, A., Mastronuzzi, A., DICER1 Syndrome and Cancer Predisposition: From a Rare Pediatric Tumor to Lifetime Risk, <<FRONTIERS IN ONCOLOGY>>, 2021; 10 (10): 1-7. [doi:10.3389/fonc.2020.614541] [https://hdl.handle.net/10807/330022]
File in questo prodotto:
File Dimensione Formato  
fonc-10-614541.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 499.46 kB
Formato Adobe PDF
499.46 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/330022
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 67
  • ???jsp.display-item.citation.isi??? 59
social impact